A major growth catalyst was the FDA approval of Dupixent as the first biologic treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype, opening a new market segment
If you've been worried about semaglutide side effects or are simply looking for a more supportive experience, explore our weight loss programmes today
Access Our Full Peptide Catalog Create a free account to view all products, detailed research insights, and exclusive pricing discounts reserved for members
The process protects patient safety
Such decisions require careful discussion with your healthcare provider, considering your diabetes control, weight management goals, and overall side effect profile
These studies could pave the way for new, targeted therapies